Talis Biomedical (NASDAQ:TLIS) Shares Down 17.4% – What’s Next?

Talis Biomedical Co. (NASDAQ:TLIS)’s share price traded down 17.4% during mid-day trading on Tuesday . The stock traded as low as $1.57 and last traded at $1.57. 5,310 shares changed hands during trading, an increase of 6% from the average session volume of 4,989 shares. The stock had previously closed at $1.90.

Talis Biomedical Stock Performance

The company’s 50 day moving average price is $1.76 and its 200 day moving average price is $3.16. The company has a market cap of $2.86 million, a price-to-earnings ratio of -0.06 and a beta of 1.52.

Institutional Investors Weigh In On Talis Biomedical

A hedge fund recently raised its stake in Talis Biomedical stock. BML Capital Management LLC boosted its position in Talis Biomedical Co. (NASDAQ:TLIS) by 481.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 248,702 shares of the company’s stock after acquiring an additional 205,959 shares during the period. Talis Biomedical accounts for 0.3% of BML Capital Management LLC’s portfolio, making the stock its 24th largest position. BML Capital Management LLC owned 13.66% of Talis Biomedical worth $460,000 at the end of the most recent reporting period. 43.77% of the stock is owned by institutional investors and hedge funds.

Talis Biomedical Company Profile

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.